Docoh
Loading...

AMGN AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Company profile

Ticker
AMGN
Exchange
Website
CEO
Robert Bradway
Employees
Incorporated
Location
Fiscal year end
Former names
AMGEN
SEC CIK
IRS number
953540776

AMGN stock data

(
)

Calendar

27 Apr 21
4 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from AMGEN earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 6.11B 6.11B 6.11B 6.11B 6.11B 6.11B
Cash burn (monthly) 51.33M 131.25M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 212.34M 542.91M n/a n/a n/a n/a
Cash remaining 5.9B 5.57B n/a n/a n/a n/a
Runway (months of cash) 114.9 42.4 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
18 May 21 Austin Wanda M Common Stock Grant Aquire A No No 0 837 0 4,031
18 May 21 Eckert Robert Common Stock Grant Aquire A No No 0 837 0 13,199
18 May 21 Garland Greg C. Common Stock Grant Aquire A No No 0 837 0 9,861
18 May 21 Holley Charles M Common Stock Grant Aquire A No No 0 837 0 5,093.442

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

75.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2143 2151 -0.4%
Opened positions 142 242 -41.3%
Closed positions 150 173 -13.3%
Increased positions 882 880 +0.2%
Reduced positions 825 749 +10.1%
13F shares
Current Prev Q Change
Total value 107.27B 100.65B +6.6%
Total shares 431.88M 437.75M -1.3%
Total puts 3.94M 4.08M -3.6%
Total calls 3.91M 3.65M +7.1%
Total put/call ratio 1.0 1.1 -10.0%
Largest owners
Shares Value Change
BLK Blackrock 48.77M $12.13B +2.0%
Vanguard 47.21M $11.75B -0.0%
Capital Research Global Investors 32.62M $8.12B +2.7%
STT State Street 29.69M $7.39B -1.3%
Primecap Management 16.67M $4.15B -1.8%
FMR 11.24M $2.8B -18.4%
MS Morgan Stanley 9.96M $2.48B +2.2%
Geode Capital Management 9.68M $2.4B +10.0%
NTRS Northern Trust 7.75M $1.93B -2.2%
WFC Wells Fargo & Co. 7.64M $1.9B +0.3%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -5.67M EXIT
Charles Schwab Investment Management 6.37M +3.59M +129.2%
FMR 11.24M -2.54M -18.4%
FIL 1.95M +1.1M +129.0%
BEN Franklin Resources 2.95M +1.1M +59.0%
BLK Blackrock 48.77M +966.28K +2.0%
Geode Capital Management 9.68M +879.18K +10.0%
Capital Research Global Investors 32.62M +856.24K +2.7%
D. E. Shaw & Co. 838K +665.06K +384.6%
GWL Great West Life Assurance 21.54K -608.96K -96.6%

Financial report summary

?
Management Discussion
  • Future sales of our products will depend in part on the factors discussed below and in the following sections of this report: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview and Selected Financial Information; and (ii) Part II, Item 1A. Risk Factors; and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2020: (i) Item 1. Business—Marketing, Distribution and Selected Marketed Products, (ii) Item 1A. Risk Factors and (iii) Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales.
  • The decrease in ENBREL sales for the three months ended March 31, 2021, was driven by favorable changes to estimated sales deductions in the prior year, lower unit demand and lower net selling price. For the remainder of 2021, we expect the trend of volume and net selling price declines to continue as compared to the prior year.
  • We are involved in patent litigation with the two companies seeking to market their FDA-approved biosimilar versions of ENBREL. See Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020. Companies with approved biosimilar versions of ENBREL may seek to enter the U.S. market if we are not ultimately successful in our litigations, or even earlier. Other companies are also developing proposed biosimilar versions of ENBREL.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abroad, addressing, adenocarcinoma, administering, America, American, AMGEVITA, antikickback, Asia, assay, attempt, back, bemarituzumab, Biden, bill, BIO, biological, brand, Breakthrough, bundled, Canadian, cap, capped, CMS, companion, Congressional, construction, copay, COVID, debated, decide, defendant, Deficiency, defray, delivery, easily, eligible, encourage, encouraging, epidermal, erosion, ESRD, EU, evidentiary, factor, failing, Fee, fewer, fibroblast, fluoropyrimidine, foreseeable, found, Franklin, gastric, gastroesophageal, gave, group, homolog, impossible, incorrect, increasingly, indirect, individual, inflation, instructing, invited, IPR, kidney, Kirsten, leucovorin, light, Lilly, logistical, Lupin, mandatory, Maryland, maximum, meaningful, Merger, metastatic, MFN, missed, narrower, nationwide, negotiate, negotiated, nonbiologic, nonfederal, OECD, oncogene, original, overcome, overexpressing, overseeing, oxaliplatin, passed, payer, PDUFA, penalize, penalty, Pharmacy, phototherapy, power, preemptive, preferred, Prime, Prinston, Priority, procedural, Prospective, pushed, quickly, rat, rebate, receptor, referencing, Register, regulated, renal, repeat, repeated, Rescue, sarcoma, Secretary, Senate, Sensipar, shift, shown, slower, solicited, statute, Step, submission, suggest, taxation, TDAPA, test, threat, today, transaction, transparency, transplantation, tumor, unpatentable, unsuccessful, User, USPTO, utilization, vaccinate, vaccination, viral, voluntary, Western
Removed: activated, advice, Aid, allocated, AMGEVITATM, anniversary, assessing, attributed, block, budget, celebrating, closed, closing, collaborative, collectability, collected, commercialization, community, compulsory, conclusion, conducting, Corlanor, cybersecurity, declaration, deem, Department, deploy, disconnect, discounted, disposable, dissemination, dosing, downturn, efficiency, emergency, enacting, engineering, equally, essential, European, exacerbate, exceeded, exert, exhibited, existence, flexibility, floating, focusing, frequently, globe, goal, governing, historically, history, hypothetical, IMLYGIC, Immunex, impair, imposed, improving, incentivize, incident, influence, infrastructure, initiation, intensity, intent, interval, investee, ivabradine, jointly, Judge, Keytruda, laherparepvec, low, Magistrate, manufactured, matured, medicine, month, national, obtain, outage, passage, payor, pediatric, perform, personal, phase, platform, prepaid, presence, pressure, procurement, prohibit, proposal, propose, proprietary, protect, protocol, put, ranging, recession, recommendation, recording, redeem, redeemed, redemption, reducing, relation, reliability, remanded, repaid, replacing, representation, representing, retaliatory, return, revert, revised, screening, sensitive, sensitivity, shareholder, single, site, size, sotorasib, Southern, Stafford, stakeholder, stated, suspended, suspending, sustained, talimogene, tender, tentatively, Thousand, transportation, turn, unauthorized, unemployment, unpaid, vendor, voting, workforce

Patents

GRANT
Utility
Pegylated carfilzomib compounds
3 Aug 21
Inventors: Gary Luehr, Shabbir T. Anik, Ge Peng, Irina Dotsenko, Pasit Phiasivongsa, Dante Romanini
GRANT
Utility
Wearable injector with sterile adhesive patch
3 Aug 21
An adhesive patch for a drug delivery device with a bacteria impermeable sterility margin surrounding an edge surface of the adhesive patch is disclosed, as well as a drug delivery device fixed to such an adhesive patch and a method of assembling a drug delivery device with such an adhesive patch.
GRANT
Utility
Process control systems and methods for use with filters and filtration processes
3 Aug 21
Systems and methods used to control tangential flow filtration are provided, including control systems and methods for use with connected systems with upstream processing units, such as chromatography processing units, in fluid communication with a tangential flow filtration processing unit.
GRANT
Utility
Methods and compositions for treating tumor diseases
3 Aug 21
The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods.
GRANT
Utility
High titer recombinant AAV vector production in adherent and suspension cells
3 Aug 21
The present invention is directed to an in vitro method of producing a recombinant AAV virion in a mammalian host cell that comprises a functional adenoviral E1A gene and rAAV virions made by the method.